Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-9 experience

被引：8

作者：

Lee, Eudocia Q. ^{[1
]}

Selig, Wendy ^{[2
]}

Meehan, Clair ^{[3
]}

Bacha, Jeffrey ^{[4
]}

Barone, Amy ^{[5
]}

Bloomquist, Erik ^{[6
]}

Chang, Susan M. ^{[7
]}

de Groot, John F. ^{[8
]}

Galanis, Evanthia ^{[9
]}

Hassan, Islam ^{[10
]}

Kalidas, Chitkala ^{[11
]}

Khasraw, Mustafa ^{[12
]}

Kvedar, Joseph C. ^{[13
]}

Lassman, Andrew B. ^{[14
,15
]}

Puduvalli, Vinay ^{[8
]}

Sahebjam, Solmaz ^{[16
]}

Schwamm, Lee H. ^{[17
]}

Tamir, Sharon ^{[18
]}

Welch, Mary ^{[14
,15
]}

Yung, W. K. Alfred ^{[8
]}

Zadeh, Gelareh ^{[19
]}

Arons, David ^{[3
]}

Wen, Patrick Y. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA

[2] WSCollaborative, Mclean, VA USA

[3] Natl Brain Tumor Soc, Newton, MA USA

[4] Edison Oncol Holding Corp, Menlo Pk, CA USA

[5] US FDA, Off Hematol & Oncol Prod, Silver Spring, MD USA

[6] US FDA, Off Biostat, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

[9] Mayo Clin, Div Med Oncol, Rochester, MN USA

[10] Agios Pharmaceut, Cambridge, MA USA

[11] Bayer Pharmaceut, Hillsborough, NJ USA

[12] Duke Univ, Preston Robert Tisch Brain Tumor Ctr Duke, Dept Neurosurg, Med Ctr, Durham, NC USA

[13] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA

[14] Columbia Univ, Dept Neurol, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA

[15] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA

[16] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA

[17] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA

[18] Karyopharm Therapeut Inc, Newton, MA USA

[19] MacFeeters Hamilton Ctr Neurooncol, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

NEURO-ONCOLOGY | 2021年 / 23卷 / 08期

关键词：

clinical trials; COVID-19; decentralization; telemedicine; TELEMEDICINE; PARTICIPATION;

D O I：

10.1093/neuonc/noab082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated including the US Food and Drug Administration (FDA), academic and community clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and representatives from the Society for Neuro-Oncology and the National Cancer Institute. This report summarizes the workshop and proposes ways to incorporate lessons learned from COVID-19 to brain tumor clinical trials including the increased use of telemedicine and decentralized trial models as opportunities for practical innovation with potential long-term impact on clinical trial design and implementation.

引用

页码：1252 / 1260

页数：9

共 6 条

[1] Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Chang, Susan M.
Lamborn, Kathleen R.
Kuhn, John G.
Yung, W. K. Alfred
Gilbert, Mark R.
Wen, Patrick Y.
Fine, Howard A.
Mehta, Minesh P.
DeAngelis, Lisa M.
Lieberman, Frank S.
Cloughesy, Timothy F.
Robins, H. Ian
Abrey, Lauren E.
Prados, Michael D.
[J]. NEURO-ONCOLOGY, 2008, 10 (04) : 631 - 642
[2] Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)
Wen, Patrick Y.
Cloughesy, Timothy F.
Ellingson, Benjamin M.
Reardon, David A.
Fine, Howard A.
Abrey, Lauren
Ballman, Karla
Bendszuz, Martin
Buckner, Jan
Chang, Susan M.
Prados, Michael D.
Pope, Whitney B.
Sorensen, Alma Gregory
van den Bent, Martin
Yung, Wai-Kwan Alfred
[J]. NEURO-ONCOLOGY, 2014, 16 : 36 - 47
[3] Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)
Helfer, Jennifer L.
Wen, Patrick Y.
Blakeley, Jaishri
Gilbert, Mark R.
Armstrong, Terri S.
[J]. NEURO-ONCOLOGY, 2016, 18 : 26 - 36
[4] MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC)
Poussaint, Tina Young
Kocak, Mehmet
Vajapeyam, Sridhar
Packer, Roger I.
Robertson, Richard L.
Geyer, Russell
Haas-Kogan, Daphne
Pollack, Ian F.
Vezina, Gilbert
Zimmerman, Robert
Cha, Soonmee
Patay, Zoltan
Boyett, James M.
Kun, Larry E.
[J]. NEURO-ONCOLOGY, 2011, 13 (04) : 417 - 427
[5] Race and prognosis of brain tumor patients entering multicenter clinical trials - A report from the Radiation Therapy Oncology Group
Simpson, JR
Scott, CB
Rotman, M
Curran, WJ
Constine, LS
Fischbach, AJ
Asbell, SO
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (02): : 114 - 120
[6] UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP)
Siegel, Christine
Aboud, Orwa
Brown, Miranda
Chung, Hye-Jung
Raffeld, Mark
Crandon, Sonja
Ji, Ming
Levine, Jason
Vera, Elizabeth
Patel, Snehal
Reyes, Jennifer
Armstrong, Terri
Xi, Liqiang
Acquaye, Alvina
Boris, Lisa
Briceno, Nicole
Garren, Nancy
Romo, Carlos
Quezado, Martha
Wu, Jing
Theeler, Brett
Gilbert, Mark
[J]. NEURO-ONCOLOGY, 2018, 20 : 170 - 170

← 1 →